United Therapeutics Corporation (NASDAQ:UTHR)’s President and Chief Operating Officer, Roger Jeffs, reported a stock disposition of 50,000 shares in Common Stock yesterday. The sale was executed directly and in two steps, first unloading 30,930 shares for a weighted average price of $96.98 per share, while selling the remaining 19,070 shares for a weighted average price of $95.05 per share. The insider also exercised his use of stock options for the transaction, as he did many times before. Jeffs has been one of the most active insiders at United Therapeutics this year, having disposed of 10,000 share of Common Stock just three weeks ago, for a price of $93.06 per share.
On another note, this quarter showed very positive improvements regarding shareholding hedge funds at the $4.5 billion market cap biotechnology firm. Paul Orlin and Alex Porter entered a new shareholder position with their hedge fund Amici Capital, having recently acquired 342,399 United shares, with an estimated value of $32.1 million and accounting for 1.05% of the portfolio.